
Pfizer (NYSE: PFE) has issued a statement on a false press release related to drug pricing that was reported on …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

